Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

FAST-XDR-DETECT

Financiado

Cerrado

Development of a two approach plate system for the fast and simultaneous detecti...

Development of a two approach plate system for the fast and simultaneous detection of MDR and XDR M. tuberculosis Tuberculosis (TB) continues being a leading cause of death due to a single infectious disease agent. The HIV/AIDS pandemic and the emergence of drug resistance are compounding factors that hinder the control of the disease. Associ... ver más

31/01/2012

ITM

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

INSTITUUT VOOR TROPISCHE GENEESKUNDE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 4 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2012-01-31 No tenemos la información de la convocatoria

0% 74% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

4 Participantes

ITM

0.00€ | Lider

LIO

N.D. | Participante

HZI

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TM-REST A new platform for fast molecular detection of MDR and XDR r... 4M€ Cerrado

mfloDx Adaptable Multiflow Diagnostic Platform to Genetically Ident... 71K€ Cerrado

Tuberculini A novel in vitro diagnostic test for drug resistant tubercul... 71K€ Cerrado

mfloDx An Adaptable Multiflow Diagnostic Platform to Genetically Id... 4M€ Cerrado

PTQ2018-009754 Investigación de nuevas herramientas de diagnóstico clínico... 78K€ Cerrado

RAPID Rapid Antimicrobial susceptibility testing and phylogenetic... 150K€ Cerrado

Líder del proyecto

INSTITUUT VOOR TROPISCHE GENEESKUNDE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Tuberculosis (TB) continues being a leading cause of death due to a single infectious disease agent. The HIV/AIDS pandemic and the emergence of drug resistance are compounding factors that hinder the control of the disease. Associated with this problem is the emergence of multidrug-resistant (MDR) strains of Mycobacterium tuberculosis, defined as strains resistant to at least isoniazid and rifampicin, the most valuable drugs in the treatment of the disease. More recently, the appearance of extensively drug resistant (XDR) strains has been reported. These strains, in addition to being MDR, are also resistant to key second-line drugs. Patients, especially HIV patients, harbouring XDR strains have virtually no treatment options. New and improved methods for fast detection of drug resistance are urgently needed. This project will develop a twofold-approach system for the fast and simultaneous detection of MDR and XDR strains based on a rapid phenotypic assay and a genotypic test. Colorimetric methods, which have been previously validated by our group for first-line drug susceptibility testing, will be developed for key second-line drugs involved in XDRTB. Once set up, these methods will be further elaborated for direct application to sputum specimens. The molecular tool will be based on a modification of the novel technology named detection of immobilized amplified product in one phase system. This single step amplification method will be developed in a versatile microtitre well strip format for detection first of MDR and then of XDR strains. The tools will be then validated in different settings and prospectively evaluated in target populations. The project will contribute to the currently available armamentarium for rapid detection of drug resistant TB and will introduce new tools for the detection of the recently-described and highly-lethal XDRTB. It will also contribute to our knowledge on the mechanisms of M. tuberculosis resistance to second-line drugs.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores